136992-21-7

Usage

Uses

Used in Pharmaceutical Industry:
(R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE is used as a pharmaceutical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs.
Used in Organic Chemistry:
(R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE is used as a building block in organic chemistry, enabling the creation of novel compounds and advancing the field of chemical research.
Used in Drug Discovery:
(R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE is utilized in drug discovery for its potential applications in developing new therapeutic agents, thanks to its unique chemical properties and structure.

InChI:InChI=1/C11H21NO4/c1-11(2,3)16-10(14)12-5-7-15-9(8-12)4-6-13/h9,13H,4-8H2,1-3H3/t9-/m1/s1

Upstream product

• 766539-28-0 2-(4-(tert-butoxycarbonyl)morpholin-2-yl)acetic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132995-76-7 (2-hydroxyethyl)-morpholine 
• 112887-43-1 2-(2-hydroxyethyl)-4-benzylmorpholine 
• 503601-25-0 (±)-ethyl 2-(morpholin-2-yl)acetate 
• 73933-19-4 ethyl 4-(phenylmethyl)-2-morpholineacetate 

Downstream Products

• 1033219-23-6 WYE-114152 
• 1033219-19-0 1-(3-methoxyphenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-02-1 1-(4-fluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-08-7 1-(2,4-difluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-15-6 1-{2-[(2R)-morpholin-2-yl]ethyl}-3-(2,4,6-trifluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-81-9 4-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-83-1 5-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-86-4 5-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-89-7 4-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-92-6 1-(2-morpholin-2-ylethyl)-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-96-0 1-{2-[(2R)-morpholin-2-yl]ethyl}-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-94-8 1-{2-[(2S)-morpholin-2-yl]ethyl}-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1257853-70-5 tert-butyl 2-(2-oxoethyl)morpholine-4-carboxylate 
• 1398495-52-7 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoic acid 

Relevant academic research and scientific papers

PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

BENZO[B]FURANS AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I).

SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors of Formula (I).

Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152)

Sequential modification of the previously identified 4-[3-aryl-2,2-dioxido- 2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols led to the identification of a new series of 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro- 2,1,3-benzothiadiazole 2,2-dioxides that are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound 10b (WYE-114152) had low nanomolar hNET potency (IC50 = 15 nM) and good selectivity for hNET over hSERT (>430-fold) and hDAT (>548-fold). 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.